Alpha-synuclein
From Proteopedia
(Difference between revisions)
| Line 22: | Line 22: | ||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| - | [[6flt]], [[6h6b]], [[6a6b]], [[6cu7]], [[6cu8]], [[6rt0]], [[6rtb]], [[6sst]], [[6ssx]], [[6xyo]], [[6xyp]], [[6xyq]], [[6osj]], [[6osl]], [[6osm]] – hSyn – human - Cryo EM<br /> | + | [[6flt]], [[6h6b]], [[6a6b]], [[6cu7]], [[6cu8]], [[6l1t]], [[6l1u]], [[6l4s]], [[6lrq]],[[6rt0]], [[6rtb]], [[6sst]], [[6ssx]], [[6xyo]], [[6xyp]], [[6xyq]], [[6osj]], [[6osl]], [[6osm]], [[7nca]], [[7ncg]], [[7nch]], [[7nci]], [[7ncj]], [[7nck]] – hSyn – human - Cryo EM<br /> |
[[2n0a]] – hSyn – NMR<br /> | [[2n0a]] – hSyn – NMR<br /> | ||
[[6ufr]], [[6peo]], [[6pes]] – hSyn (mutant) - Cryo EM<br /> | [[6ufr]], [[6peo]], [[6pes]] – hSyn (mutant) - Cryo EM<br /> | ||
Revision as of 11:20, 14 March 2021
| |||||||||||
3D Structures of alpha-synuclein
Updated on 14-March-2021
6flt, 6h6b, 6a6b, 6cu7, 6cu8, 6l1t, 6l1u, 6l4s, 6lrq,6rt0, 6rtb, 6sst, 6ssx, 6xyo, 6xyp, 6xyq, 6osj, 6osl, 6osm, 7nca, 7ncg, 7nch, 7nci, 7ncj, 7nck – hSyn – human - Cryo EM
2n0a – hSyn – NMR
6ufr, 6peo, 6pes – hSyn (mutant) - Cryo EM
2m55 – hSyn residues 1-19 + calmodulin – NMR
6i42 – hSyn residues 48-60 + cyclophilin A
5crw – hSyn residues 31-41 + protein disulfide isomerase
6ct7 – hSyn residues 1-10 + antibody
2x6m – hSyn residues 132-140 + antibody
3q25, 3q26, 3q27, 3q28, 3q29 – hSyn peptide/MBP
3q26 – hSyn residues 10-42/MBP
4r0u, 4r0w, 4rik, 4ril - hSyn amyloid-forming peptide
4znn - hSyn amyloid-forming peptide (mutant)
References
- ↑ Logan T, Bendor J, Toupin C, Thorn K, Edwards RH. alpha-Synuclein promotes dilation of the exocytotic fusion pore. Nat Neurosci. 2017 May;20(5):681-689. doi: 10.1038/nn.4529. Epub 2017 Mar 13. PMID:28288128 doi:http://dx.doi.org/10.1038/nn.4529
- ↑ Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010 Sep 24;329(5999):1663-7. doi: 10.1126/science.1195227. Epub 2010, Aug 26. PMID:20798282 doi:http://dx.doi.org/10.1126/science.1195227
- ↑ Butler B, Saha K, Rana T, Becker JP, Sambo D, Davari P, Goodwin JS, Khoshbouei H. Dopamine Transporter Activity Is Modulated by alpha-Synuclein. J Biol Chem. 2015 Dec 4;290(49):29542-54. doi: 10.1074/jbc.M115.691592. Epub 2015, Oct 6. PMID:26442590 doi:http://dx.doi.org/10.1074/jbc.M115.691592
- ↑ Xu L, Pu J. Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Parkinsons Dis. 2016;2016:1720621. doi: 10.1155/2016/1720621. Epub 2016 Aug 17. PMID:27610264 doi:http://dx.doi.org/10.1155/2016/1720621
- ↑ Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease. Front Mol Neurosci. 2019 Dec 5;12:299. doi: 10.3389/fnmol.2019.00299. eCollection, 2019. PMID:31866823 doi:http://dx.doi.org/10.3389/fnmol.2019.00299
- ↑ Guerrero-Ferreira R, Taylor NMI, Mona D, Ringler P, Lauer ME, Riek R, Britschgi M, Stahlberg H. Cryo-EM structure of alpha-synuclein fibrils. Elife. 2018 Jul 3;7. pii: 36402. doi: 10.7554/eLife.36402. PMID:29969391 doi:http://dx.doi.org/10.7554/eLife.36402
